Introduction {#s1}
============

Among the dipeptidyl peptidase-4 (DPP-4) inhibitors that are widely used, sitagliptin is the first to be approved for patients with type 2 diabetes mellitus (T2DM) on insulin therapy. Despite its established position, relatively few clinical studies of sitagliptin have been performed. These include a US study of patients who were predominantly on once-daily long-acting, insulin therapy \[[@R01]\], a Japanese study of patients on mixed insulin therapy \[[@R02]\], and observational studies with small populations \[[@R03], [@R04]\].

T2DM patients receiving insulin often have a longer disease duration and a reduced insulin secretion capacity. Because their baseline characteristics and insulin doses vary, clinical trials alone do not provide enough information about these patients \[[@R05]\]. Moreover, the effectiveness of DPP-4 inhibitors at stimulating an insulin response in patients with compromised insulin secretion on insulin therapy has not been examined. A small-scale randomized controlled trial (RCT) has shown that sitagliptin improves hemoglobin A~1c~ (HbA~1c~) and postprandial glucose levels in patients with type 1 diabetes \[[@R06]\]. The effect of sitagliptin in increasing glucagon-like peptide 1 (GLP-1), which results in inhibition of glucagon secretion rather than stimulation of insulin secretion, has attracted attention \[[@R07], [@R08]\].

RCTs play a significant role in evidence-based medicine. However, such trials exclude patients who do not meet the specified inclusion criteria, even though these patients are often important in the real-world clinical setting. This is particularly relevant for T2DM, since pathological conditions vary widely in patients with this disease, making it difficult to investigate all patient types in a single RCT.

In the present study, we investigated the efficacy and safety of insulin-sitagliptin combination therapy in a multicenter study to verify the usefulness of this regimen for T2DM patients on various types of insulin therapy. Our findings add some useful information to the evidence already established by RCTs.

Methods {#s2}
=======

This retrospective study included patients receiving sitagliptin in addition to insulin from November 2011 to March 2013 at 36 diabetes clinics in Kanagawa Prefecture, Japan. Sitagliptin was started if the attending physician considered that insulin was not achieving adequate glycemic control. Glycemic control, the insulin dose, concomitant drugs, blood pressure (BP), body weight, and laboratory data were analyzed, as well as the occurrence of adverse events. Eligible patients had been on insulin for 6 months or longer, with an HbA~1c~ of 7.0% (53 mmol/mol) or higher, and had undergone follow-up for at least 6 months.

The primary endpoint was the change of HbA~1c~. To explore factors contributing to the improvement of HbA~1c~ by insulin-sitagliptin combination therapy, multiple regression analysis was performed with the following variables: age, sex, baseline body mass index (BMI), duration of insulin therapy, baseline HbA~1c~, daily insulin dose, presence/absence of diabetic neuropathy, smoking, alcohol consumption, and concomitant use of sulfonylureas (SUs), biguanides (BGs), alpha-glucosidase inhibitors (α-GIs), and thiazolidinediones (TZDs). Patients who had previously been treated with a DPP-4 inhibitor were excluded.

Results are reported as mean ± standard deviation. All analyses were carried out using SPSS version 19 software (SPSS Inc., Chicago, IL, USA). The effect of sitagliptin treatment was assessed by one-way analysis of variance and P \< 0.05 was accepted as indicating statistical significance.

This study was registered with the Clinical Trials Registry (http://clinicaltrials.gov; NCT01855087) and was undertaken in accordance with the Ethical Guidelines for Clinical Studies of the Japanese Ministry of Health, Labor, and Welfare. Informed consent was not required because this was a retrospective analysis.

Results {#s3}
=======

A total of 1,169 case record forms were collected. Then patients with sitagliptin treatment for \< 6 months (n = 54), baseline HbA~1c~ \< 7.0% (53 mmol/mol) (n = 81), and incomplete data (n = 30) were excluded. The remaining 1,004 patients were available for analysis and their characteristics are shown in [Table 1](#T1){ref-type="table"}. Based on the results of Japanese clinical studies employing sitagliptin, the drug was up-titrated in some patients from a starting dose of 50 mg to 100 mg if the former dose was not effective, while a low dose of 25 mg was selected for 65 patients with impaired renal function \[[@R09]\]. Among the 1,004 patients, medications other than insulin and sitagliptin were altered in 185 patients, including 144 who discontinued α-GIs or TZDs and 41 who received add-on biguanides.

###### Characteristics of the Subjects

  --------------------------------------------- -----------------------------
  Age, years                                    63.9 ± 12.1
  Sex, male/female                              521/483
  Body mass index                               25.5 ± 4.6
  Hemoglobin A~1c~, % (mmol/mol)                8.69 ± 1.31 (72 ± 12)
  Fasting blood glucose, mg/dL (mmol/L)         184.3 ± 70.5 (10.23 ± 3.91)
  Serum C-peptide, ng/mL (nmol/L)               1.47 ± 1.03 (0.49 ± 0.34)
  Duration of diabetes, years                   17.1 ± 9.0
  Duration of insulin treatment, years          6.3 ± 5.6
  Smoking, %                                    23.1
  Alcohol consumption, %                        22.7
  Complications, %                              
    Diabetic neuropathy                         33.6
    Diabetic retinopathy                        33.4
    Diabetic nephropathy                        38.5
    Cerebrovascular disease                     7.6
    Myocardial infarction/angina pectoris       17.3
    Arteriosclerosis obliterans                 8.8
    Hypertension                                57.7
    Dyslipidemia                                61.4
    Hepatic steatosis                           30.0
  Insulin regimen, n                            
    Long-acting insulin, once daily             215
    Mixed insulin, twice daily                  162
    Three times daily, no long-acting insulin   209
    Basal-bolus insulin                         334
  Concomitant oral medications, n               
    Sulfonylureas                               222
    Biguanides                                  397
    Thiazolidinediones                          64
    Alpha-glucosidase inhibitors                184
    None                                        418
  Dose of sitagliptin, n                        
    25 mg throughout                            65
    Up-titration from 25 mg to 50 mg            83
    50 mg throughout                            809
    Up-titration from 50 mg to 100 mg           47
  --------------------------------------------- -----------------------------

Data are mean ± standard deviation unless otherwise indicated.

After starting insulin-sitagliptin combination therapy, HbA~1c~ decreased significantly from the baseline value of 8.69±1.31% (72 ± 12 mmol/mol) to 8.30±1.23% (67 ± 11 mmol/mol), 7.99±1.25% (64 ± 11 mmol/mol), and 7.95±1.25% (64 ± 11 mmol/mol) at 1 month, 3 months, and 6 months, respectively. Body weight showed a slight, but significant, increase of 0.1 kg, while there were no changes in the doses of insulin or the other oral antidiabetic drugs ([Fig. 1](#F1){ref-type="fig"}).

![Changes in hemoglobin A~1c~, body weight, and insulin dose (n = 1,004). Data are the mean ± standard deviation. Analysis of variance vs. baseline. \*P \< 0.05. M: months.](jocmr-07-607-g001){#F1}

Hypoglycemic symptoms were noted in 7.4% of the subjects, but were not severe. Other adverse events included abdominal distension (0.9%) and constipation (0.4%). With regard to changes in laboratory values, there was a significant decrease of systolic BP, fasting blood glucose, glycated albumin, alkaline phosphatase, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, while there was a significant increase of uric acid and serum creatinine ([Table 2](#T2){ref-type="table"}).

###### Changes in Laboratory Values

  Clinical parameter                          n     Baseline         1 month            3 months           6 months           Difference between baseline and 6 months
  ------------------------------------------- ----- ---------------- ------------------ ------------------ ------------------ ------------------------------------------
  Systolic BP, mm Hg                          923   130.82           130.85             130.38             130.28             
  Diastolic BP, mm Hg                         923   74.97            74.66^a^           74.03^a^           74.22^a^           -0.75
  Fasting blood glucose, mg/dL (mmol/L)       199   181.35 (10.06)   160.62 (8.91)^a^   164.81 (9.15)^a^   160.9 (8.93)^a^    -20.45 (-1.13)
  Serum C-peptide, ng/dL (nmol/L)             53    0.91 (0.30)      0.98 (0.32)        1 (0.33)           0.96 (0.32)        
  Glycated albumin, %                         53    23.2             21.61^a^           21.05^a^           21.03^a^           -2.17
  Aspartate aminotransferase, IU/L (µkat/L)   773   27.62 (0.46)     26.41 (0.44)       27.02 (0.45)       27.56 (0.46)       
  Alanine aminotransferase, IU/L (µkat/L)     770   24.66 (0.41)     24.11 (0.40)       24.79 (0.41)       24.22 (0.40)       
  Gamma-glutamyl transpeptidase, IU/L         703   44.12            42.22              42.12              43.47              
  Alkaline phosphatase, mg/dL                 175   260.05           254.16^a^          241.82^a^          241.83^a^          -18.22
  Total cholesterol, mg/dL (mmol/L)           453   194.72 (5.04)    191.56 (4.96)^a^   190.26 (4.93)^a^   191.39 (4.96)^a^   -3.33 (-0.08)
  LDL cholesterol, mg/dL (mmol/L)             733   109.66 (2.84)    109.02 (2.82)      108.67 (2.81)      109.08 (2.83)      
  HDL cholesterol, mg/dL (mmol/L)             794   55.62 (1.44)     55.05 (1.43)^a^    54.8 (1.42)^a^     54.72 (1.42)^a^    -0.90 (-0.02)
  Triglycerides, mg/dL (mmol/L)               805   164.12 (1.85)    153.61 (1.74)^a^   153.3 (1.73)^a^    155.33 (1.76)^a^   -8.79 (-0.09)
  Uric acid, mg/dL (µmol/L)                   331   5.05 (300.40)    5.18 (308.13)^a^   5.32 (316.46)^a^   5.27 (313.49)^a^   +0.25 (+13.09)
  Creatinine, mg/dL (µmol/L)                  674   0.76 (67.18)     0.77 (68.07)^a^    0.78 (68.95)^a^    0.79 (69.84)^a^    +0.03 (+2.66)

^a^P \< 0.05 (analysis of variance vs. baseline). BP: blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein.

Multiple regression analysis was performed to examine factors related to the change of HbA~1c~ within 6 months of starting sitagliptin. Complete baseline data on the age, sex, BMI, duration of insulin treatment, HbA~1c~, daily insulin dose, presence/absence of diabetic neuropathy, smoking, alcohol consumption, and concomitant use of SUs, BGs, α-GIs and TZDs were available for 495 patients. These characteristics of the 495 patients were similar to those of the main study population (data not shown).

A high HbA~1c~ at baseline was the strongest contributor to reduction of HbA~1c~ at 6 months after starting treatment with insulin-sitagliptin combination therapy ([Table 3](#T3){ref-type="table"}). In addition, BMI and age made slight, but significant, contributions to the reduction of HbA~1c~ ([Table 3](#T3){ref-type="table"}).

###### Multiple Regression Analysis of Delta Hemoglobin A~1c~ After 6 Months of Insulin-Sitagliptin Combination Therapy in 495 Patients With Complete Data

  Factor                                 Beta value   P value     Standardized beta value
  -------------------------------------- ------------ ----------- -------------------------
  Age                                    -0.010       0.0088      -0.124
  Female sex                             0.164        0.0802      0.080
  Baseline body mass index               0.030        0.0048      0.136
  Duration of insulin treatment, years   0.013        0.1383      0.065
  Baseline hemoglobin A~1c~              -0.400       \< 0.0001   -0.502
  Baseline daily insulin dose            0.002        0.2401      0.057
  Presence of diabetic neuropathy        0.051        0.5512      0.025
  Smoking, yes                           0.004        0.9694      0.002
  Alcohol consumption, yes               -0.004       0.9683      -0.002
  Sulfonylureas                          0.191        0.0939      0.074
  Biguanides                             -0.162       0.0720      -0.078
  Thiazolidinediones                     -0.300       0.0800      -0.072
  Alpha-glucosidase inhibitors           -0.096       0.3606      -0.037

We also performed multiple regression analysis on a cohort of 114 patients who had C-peptide data before commencement of sitagliptin therapy. This showed that C-peptide had no influence on the effectiveness of sitagliptin (data not shown).

Discussion {#s4}
==========

The Diabetes Task Force of the Kanagawa Physicians Association previously conducted a large-scale trial involving more than 1,000 patients (the ASSET-K study), which established that a higher baseline HbA~1c~, shorter disease duration, and lower baseline BMI were factors contributing to reduction of HbA~1c~ in patients receiving sitagliptin combined with another oral antidiabetic drug \[[@R10]\]. However, the factors influencing the HbA~1c~-lowering effect of sitagliptin when it is used concomitantly with insulin were not fully elucidated. Therefore, we conducted the present study to investigate this issue.

We confirmed the effectiveness and safety of combining sitagliptin with insulin in a large patient population (n = 1,004) treated in the real-world setting. HbA~1c~ decreased by 0.74% (6 mmol/mol) and body weight increased by 0.1 kg, while there were no appreciable changes in the doses of insulin or other oral antidiabetic agents. In addition, there were no episodes of severe hypoglycemia, although hypoglycemic events were reported in 7.4% of the patients. In general, the formulation, dose, and frequency of insulin administration are altered if an HbA~1c~ \< 7.0% (53 mmol/mol) is not achieved after a certain period. However, increasing the insulin dose may lead to adverse events such as weight gain and hypoglycemia. The present study demonstrated the effectiveness of insulin-sitagliptin combination therapy in the real-world setting. As well as improving HbA~1c~, there were significant reductions of systolic BP, fasting blood glucose, glycated albumin, alkaline phosphatase, total cholesterol, HDL cholesterol, and triglycerides, which suggest that sitagliptin may also exert a favorable effect on BP and the lipid profile, as reported in the ASSET-K study \[[@R14]\]. The significant increase of uric acid and serum creatinine were also in agreement with the results of the ASSET-K study, and can be explained by the fact that sitagliptin increases GLP-1, an incretin hormone with diuretic properties. In fact, a correlation between the reduction of BP and an increase of creatinine and uric acid levels has been reported \[[@R14]\].

We performed multiple regression analysis to identify patients who were likely to respond to addition of sitagliptin to insulin therapy. We analyzed various factors that had a potential influence on HbA~1c~ including diabetic neuropathy, smoking, and alcohol, because diabetic neuropathy may inhibit the effect of GLP-1 and patients who smoke or drink regularly are more likely to lead an unhealthy lifestyle with suboptimal diet and exercise. We identified a higher baseline HbA~1c~ as the strongest contributing factor, while a lower baseline BMI and older age were also significant. This is in agreement with the fact that older patients tended to have a lower BMI in our study. There was a positive correlation between the duration of diabetes and the duration of insulin therapy (Pearson's correlation coefficient = 0.40), as well as between the frequency of insulin administration and the daily insulin dose (Pearson's correlation coefficient = 0.51). Therefore, the duration of insulin therapy and the daily insulin dose were included in the multiple regression analysis as background factors, revealing that the duration of insulin therapy was not associated with the effectiveness of sitagliptin. These results support the addition of sitagliptin to insulin therapy, irrespective of the duration of insulin treatment, the daily insulin dose, concomitant medications, and the C-peptide profile. Even in patients with compromised insulin secretion, sitagliptin can still effectively stimulate insulin secretion and it also has other potential benefits. Inhibition of glucagon secretion may be involved in the efficacy of DPP-4 inhibitors for insulin-treated patients \[[@R06]\] and inhibition of glucagon secretion as a GLP-1 receptor agonist may be important in type 1 diabetes \[[@R15]\].

It has been reported that T2DM patients in East Asian countries (including Japan) have lower endogenous insulin secretion and that their BMI tends to be lower \[[@R16]\]. Kim et al reported that sitagliptin was particularly effective in the Japanese population \[[@R17]\]. In addition to the ASSET-K study, several observational studies have demonstrated the effectiveness of sitagliptin in patients with a lower BMI \[[@R11], [@R13], [@R18]\]. However, more research is needed to determine whether our results are related to ethnic factors, especially studies in non-Japanese populations.

There were some limitations of this study. First, it was retrospective. Second, all of the patients received sitagliptin and there was no control group without sitagliptin treatment. Third, markers for the assessment of beta-cell function (HOMA-beta) and the basal level of active GLP-1, which are factors that could influence the reduction of HbA~1c~ by sitagliptin therapy, were not measured in all patients. In fact, only 495 out of 1,004 patients were included in the detailed analysis, but these patients were considered to be reasonably representative of the entire population since their characteristics did not differ from those of the whole population (data not shown).

In conclusion, this study provided useful new information about the efficacy and safety of sitagliptin that can be added to the findings of relevant RCTs. We demonstrated that a higher baseline HbA~1c~ was associated with greater improvement of HbA~1c~ in patients given sitagliptin as add-on therapy to insulin, while other factors were not clinically relevant. This suggests that patients might be candidates for add-on sitagliptin therapy irrespective of their characteristics, insulin dose, and concomitant medications. Because a significant increase of body weight was not observed, sitagliptin may be added whenever the HbA~1c~ is not well controlled by insulin therapy.
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